T Cell News and Research

Latest T Cell News and Research

Bacteria barge inside guard cells and initiate a powerful immune response

Immune cells that are the body's front-line defense don't necessarily rest quietly until invading bacteria lock onto receptors on their outside skins and rouse them to action, as previously thought.

18 Apr 2007

Nanoparticles could damage DNA and lead to cancer

Tissue studies indicate that nanoparticles, engineered materials about a billionth of a meter in size, could damage DNA and lead to cancer, according to research presented at the 2007 Annual Meeting of the American Association for Cancer Research.

18 Apr 2007

Nanoparticle delivery system delivers cancer-suppressing gene in M. D. Anderson trial

A cancer-suppressing gene has been successfully delivered into the tumors of stage 4 lung cancer patients via an intravenously administered lipid nanoparticle in a phase I clinical trial at The University of Texas M. D. Anderson Cancer Center.

18 Apr 2007

Immunomedics presents results on novel immunotoxin for prostate and lung cancers

Immunomedics has presented at the 2007 Annual Meeting of the American Association for Cancer Research results on the in vitro and in vivo evaluation of a novel immunotoxin, Rap-hRS7, for the potential treatment of prostate and lung cancers.

18 Apr 2007

More effective therapies for individual cancers - personalized medicine

Genetic and epigenetic variations ensure that no two people are exactly alike, and the same holds true for any two cancers.

18 Apr 2007

Scientists tackle cancer with different approaches

Studies presented at the 2007 meeting of the American Association for Cancer Research show how researchers are using the new, as well as the natural, to help design and test new drugs to treat cancer.

18 Apr 2007

Tests predict outcome of antibiotic therapy for infections in persons with diabetes

Researchers from the University of Washington, Rosalind Franklin University of Medicine and Science, Merck Laboratories, and Mount Sinai School of Medicine have released a study suggesting that specific laboratory and clinical tests can predict outcome of antibiotic therapy for infections in persons with diabetes.

18 Apr 2007

Scientists isolate enzyme that could be used to predict survival for nasopharyngeal cancer

Mayo Clinic Cancer Center scientists, in collaboration with Chinese researchers, have isolated an enzyme that could be used to predict survival and recurrence rates for nasopharyngeal cancer -- a common cancer affecting people from Southeast Asia.

18 Apr 2007

Cell Therapeutics settles law suit with Government

Cell Therapeutics has announced that it has settled all government claims arising out of a Department of Justice investigation into allegations regarding alleged overpayments by Medicare to doctors who prescribed the anti-cancer drug, TRISENOX.

18 Apr 2007

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Evaluation of antibody responses in patients with advanced prostate cancer from these studies shows that the GVAX cell-based immunotherapy induces antibody responses to a broad array of prostate cancer- associated antigens, including some not previously known to be associated with prostate cancer.

18 Apr 2007

Taking a jab at cancer by stimulating the immune system

As the first FDA-approved cancer vaccine, designed to protect against human papillomavirus, has moved from scientific discussion to social debate, other vaccine studies are continuing to make progress.

18 Apr 2007

Bioluminescence part of new imaging technique

CNRS scientists in collaboration have developed a new technique for the in vivo imaging of neuronal function using bioluminescence, based on a GFP-aequorin fusion protein.

18 Apr 2007

Better understanding of membrane fusion

Cells constantly swap cargo bound in vesicles, miniscule membrane-enclosed packages of proteins and other chemicals. Before the swap can take place, the vesicle membrane must fuse with another membrane, creating channels packages can pass through.

18 Apr 2007

Avalon Pharmaceuticals announces results of AVN944 biomarker study

Avalon Pharmaceuticals has announced the results of an AVN944 biomarker study that utilized Avalon's proprietary AvalonRx technology to identify gene signatures that may be useful for patient stratification.

18 Apr 2007

Anemia treatment for patients with kidney disease can differ by dialysis facility type

Large, for-profit dialysis facilities appear to administer higher than necessary amounts of a medication for treating anemia in patients with kidney disease, compared to nonprofit facilities, according to a study in the April 18 issue of JAMA.

18 Apr 2007

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles.

18 Apr 2007

Clioquinol shows promise in fighting cancer

Researchers from the Barbara Ann Karmanos Cancer Institute in Detroit, MI presented strong evidence today that an antibiotic typically prescribed for Alzheimer's patients could be effective in eventually treating certain types of cancers.

18 Apr 2007

Brain tumor vaccine shows promise

A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain has shown promise in preliminary data from a clinical trial at the University of California, San Francisco.

17 Apr 2007

New hope for spinal cord injury sufferers

Spinal cord injury (SCI) is one of the most significant forms of neurotrauma with major economic and social impact.

17 Apr 2007

Thrombogenics announces agreement with Millipore for commercialization of stem cell technology

ThromboGenics NV has announced that it has completed a global license agreement with Millipore Corporation under which ThromboGenics will exclusively license its technology for production of the proprietary stem cell culture medium marketed by Millipore as RESGRO(x).

17 Apr 2007

T Cell News and Research

Latest T Cell News and Research

Bacteria barge inside guard cells and initiate a powerful immune response

Nanoparticles could damage DNA and lead to cancer

Nanoparticle delivery system delivers cancer-suppressing gene in M. D. Anderson trial

Immunomedics presents results on novel immunotoxin for prostate and lung cancers

More effective therapies for individual cancers - personalized medicine

Scientists tackle cancer with different approaches

Tests predict outcome of antibiotic therapy for infections in persons with diabetes

Scientists isolate enzyme that could be used to predict survival for nasopharyngeal cancer

Cell Therapeutics settles law suit with Government

Cell Genesys reports data from clinical trials of GVAX immunotherapy for prostate cancer

Taking a jab at cancer by stimulating the immune system

Bioluminescence part of new imaging technique

Better understanding of membrane fusion

Avalon Pharmaceuticals announces results of AVN944 biomarker study

Anemia treatment for patients with kidney disease can differ by dialysis facility type

Anadys Pharmaceuticals presents data showing ANA773 promotes anti-tumor activity of killer cells

Clioquinol shows promise in fighting cancer

Brain tumor vaccine shows promise

New hope for spinal cord injury sufferers

Thrombogenics announces agreement with Millipore for commercialization of stem cell technology

Immunology eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in